Venatorx and Roche team up to take on ‘superbugs’ with new class of antibiotics

Venatorx CEO Christopher J. Burns said his company’s new class of antibiotics “has the potential to usher in a new wave of antibacterial therapeutics and reset the clock on antimicrobial resistance.”